Research ReportsAarti Drugs Q1 Results Review - Miss On Operating Performance: Dolat Capital
ADVERTISEMENT
Aarti Drugs Q1 Results Review - Miss On Operating Performance: Dolat Capital
The brokerage expects company's earnings CAGR of 32% over FY24-26E on a low base, led by input cost stabilizing coupled with ramp-up of existing and new facilities.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.